Trial · NCT03355209
Results by group1,108
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 1,108
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
Part 1: Percent Change From Baseline in the Frequency of Seizures That Result in Drops (ESC-confirmed) in the Combined Titration and Maintenance Period (T+M) in the ZX008 0.8 mg/kg/Day Group Compared to the Placebo Group | Cohort A: Placebo | -7.59 | Full Range -100.0 to 557.1 | percent change | |
Part 1: Percent Change From Baseline in the Frequency of Seizures That Result in Drops (ESC-confirmed) in the Combined Titration and Maintenance Period (T+M) in the ZX008 0.8 mg/kg/Day Group Compared to the Placebo Group | Cohort A: ZX008 0.8 mg/kg/Day | -26.49 | Full Range -95.2 to 402.1 | percent change | |
Part 1: Percent Change From Baseline in the Frequency of Seizures That Result in Drops (ESC-confirmed) in the Combined Titration and Maintenance Period (T+M) in the ZX008 0.8 mg/kg/Day Group Compared to the Placebo Group | Cohort B: Placebo | -17.89 | Full Range -97.3 to 61.8 | percent change | |
Part 1: Percent Change From Baseline in the Frequency of Seizures That Result in Drops (ESC-confirmed) in the Combined Titration and Maintenance Period (T+M) in the ZX008 0.8 mg/kg/Day Group Compared to the Placebo Group | Cohort B: ZX008 0.8 mg/kg/Day | -34.52 | Full Range -69.4 to 45.5 | percent change | |
| Part 2: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) | Part 2: Cohort A- Overall | 83.0 | percentage of participants | ||
| Part 2: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) | Part 2: Cohort B- Overall | 96.9 | percentage of participants | ||
| Part 2: Percentage of Participants With Serious TEAEs | Part 2: Cohort A- Overall | 16.6 | percentage of participants | ||
| Part 2: Percentage of Participants With Serious TEAEs | Part 2: Cohort B- Overall | 18.8 | percentage of participants | ||
| Part 1: Percent Change From Baseline in the Frequency of Seizures That Result in Drops (ESC-confirmed) in T+M in the ZX008 0.2 mg/kg/Day Group Compared to the Placebo Group | Cohort A: Placebo | -7.59 | Full Range -100.0 to 557.1 | percent change | |
| Part 1: Percent Change From Baseline in the Frequency of Seizures That Result in Drops (ESC-confirmed) in T+M in the ZX008 0.2 mg/kg/Day Group Compared to the Placebo Group | Cohort A: ZX008 0.2 mg/kg/Day | -14.16 | Full Range -100.0 to 3307.3 | percent change | |
| Part 1: Percent Change From Baseline in the Frequency of Seizures That Result in Drops (ESC-confirmed) in T+M in the ZX008 0.2 mg/kg/Day Group Compared to the Placebo Group | Cohort B: Placebo | -17.89 | Full Range -97.3 to 61.8 | percent change | |
| Part 1: Percent Change From Baseline in the Frequency of Seizures That Result in Drops (ESC-confirmed) in T+M in the ZX008 0.2 mg/kg/Day Group Compared to the Placebo Group | Cohort B: ZX008 0.2 mg/kg/Day | -14.12 | Full Range -95.6 to 66.4 | percent change | |
Part 1: Percentage of Participants Who Achieve a >=50% Reduction From Baseline in the Frequency of Seizures That Result in Drops Comparing the ZX008 0.8 mg/kg/Day and 0.2 mg/kg/Day Groups Independently Versus Placebo | Cohort A: Placebo | 10.3 | percentage of participants | ||
Part 1: Percentage of Participants Who Achieve a >=50% Reduction From Baseline in the Frequency of Seizures That Result in Drops Comparing the ZX008 0.8 mg/kg/Day and 0.2 mg/kg/Day Groups Independently Versus Placebo | Cohort A: ZX008 0.2 mg/kg/Day | 28.1 | percentage of participants | ||
Part 1: Percentage of Participants Who Achieve a >=50% Reduction From Baseline in the Frequency of Seizures That Result in Drops Comparing the ZX008 0.8 mg/kg/Day and 0.2 mg/kg/Day Groups Independently Versus Placebo | Cohort A: ZX008 0.8 mg/kg/Day | 25.3 | percentage of participants | ||
Part 1: Percentage of Participants Who Achieve a >=50% Reduction From Baseline in the Frequency of Seizures That Result in Drops Comparing the ZX008 0.8 mg/kg/Day and 0.2 mg/kg/Day Groups Independently Versus Placebo | Cohort B: Placebo | 9.1 | percentage of participants | ||
Part 1: Percentage of Participants Who Achieve a >=50% Reduction From Baseline in the Frequency of Seizures That Result in Drops Comparing the ZX008 0.8 mg/kg/Day and 0.2 mg/kg/Day Groups Independently Versus Placebo | Cohort B: ZX008 0.2 mg/kg/Day | 36.4 | percentage of participants | ||
Part 1: Percentage of Participants Who Achieve a >=50% Reduction From Baseline in the Frequency of Seizures That Result in Drops Comparing the ZX008 0.8 mg/kg/Day and 0.2 mg/kg/Day Groups Independently Versus Placebo | Cohort B: ZX008 0.8 mg/kg/Day | 36.4 | percentage of participants | ||
Part 1: Percentage of Participants Who Achieve Improvement (Minimally, Much or Very Much Improved) in the CGI-I Scale as Assessed by Principal Investigator Comparing ZX008 0.8 and 0.2 mg/kg/Day Groups Independently Versus Placebo | Cohort A: Placebo | 33.8 | percentage of participants | ||
Part 1: Percentage of Participants Who Achieve Improvement (Minimally, Much or Very Much Improved) in the CGI-I Scale as Assessed by Principal Investigator Comparing ZX008 0.8 and 0.2 mg/kg/Day Groups Independently Versus Placebo | Cohort A: ZX008 0.2 mg/kg/Day | 44.7 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03355209/results